PF-06425090 is under clinical development by Pfizer and currently in Phase III for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase III drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how PF-06425090’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PF-06425090 vaccine is under development for the prevention of Clostridium difficile infections. The vaccine is administered via intramuscular route as powder for suspension. The vaccine candidate is genetically modified toxins in a non-sporulating strain of C. difficile that lacks the toxin genes tcdA and tcdB.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of PF-06425090’s drug-specific PTSR and LoA scores, buy the report here.